← Every company
Neurocrine Biosciences Inc Patents
What Neurocrine Biosciences Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
NBIX on carbonthat →Filings on file
52
Granted
0
Still pending
52
Filed under
3 names
52 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| CRYSTALLINE FORMSFiled as NEUROCRINE BIOSCIENCES, INC.2026-03-13SCOTT STIRN | pending |
| METHODS FOR THE ADMINISTRATION OF CERTAIN INHIBITORS OF NA V CHANNELSFiled as NEUROCRINE BIOSCIENCES, INC.2026-01-30DIETRICH HAUBENBERGER | pending |
| INGREZZA SPRINKLEFiled as NEUROCRINE BIOSCIENCES, INC.2026-01-08GEORGIE ABRAHAM GEORGE | pending |
| SOLID FORMS COMPRISING AN AMPA POSITIVE ALLOSTERIC MODULATORFiled as NEUROCRINE BIOSCIENCES, INC.2025-12-18CHRISTINA M. COSTA | pending |
| SOLID FORMS COMPRISING AN AMPA POSITIVE ALLOSTERIC MODULATORFiled as Neurocrine Biosciences, Inc.2025-12-11Christina M. COSTA | pending |
| METHODS FOR THE ADMINISTRATION OF CRF ANTAGONISTFiled as NEUROCRINE BIOSCIENCES, INC.2025-12-10EIRY W ROBERTS | pending |
| METHODS FOR THE ADMINISTRATION OF CRF ANTAGONISTFiled as NEUROCRINE BIOSCIENCES, INC.2025-12-10EIRY W. ROBERTS | pending |
| DOSAGE REGIME OF CRINECERFONT FOR TREATING CONGENITAL ADRENAL HYPERPLASIA IN A PEDIATRIC SUBJECTA61K 31/426, A61P 5/38, A61K 31/573, A61K2300/00Filed as Neurocrine Biosciences, Inc.2025-11-07Jean L. Chan | pending |
| COMPOSITIONS AND METHODS FOR DELIVERING CYCLIN-DEPENDENT KINASE-LIKE 5 PROTEINFiled as NEUROCRINE BIOSCIENCES, INC.2025-10-29HUIQUAN LI | pending |
| COMPOSITIONS AND METHODS FOR DELIVERING CYCLIN-DEPENDENT KINASE-LIKE 5 PROTEINFiled as NEUROCRINE BIOSCIENCES, INC.2025-10-29HUIQUAN LI | pending |
| COMPOSITIONS AND METHODS FOR DELIVERING SYNTAXIN-BINDING PROTEIN-1Filed as NEUROCRINE BIOSCIENCES, INC.2025-10-29DAVID PAUL DRUCKER WOLDBYE | pending |
| COMPOSITIONS AND METHODS FOR DELIVERING SYNTAXIN-BINDING PROTEIN-1Filed as NEUROCRINE BIOSCIENCES, INC.2025-10-29DAVID PAUL DRUCKER WOLDBYE | pending |
| DOSAGE REGIME OF CRINECERFONT FOR TREATING CONGENITAL ADRENAL HYPERPLASIAA61K 31/426, A61P 5/38, A61K 31/573, A61K2300/00Filed as Neurocrine Biosciences, Inc.2025-09-26Jean L. Chan | pending |
| CHEMICALLY MODIFIED PEPTIDES AND USE THEREOFFiled as NEUROCRINE BIOSCIENCES, INC.2025-09-18ADAM R. MEZO | pending |
| CHEMICALLY MODIFIED PEPTIDES AND USE THEREOFFiled as NEUROCRINE BIOSCIENCES, INC.2025-09-18ADAM R. MEZO | pending |
| SOLID FORMS COMPRISING A NR2B NAM ANTAGONISTFiled as NEUROCRINE BIOSCIENCES, INC.2025-09-15CHRISTINA M. COSTA | pending |
| PHARMACEUTICAL FORMULATIONSFiled as NEUROCRINE BIOSCIENCES, INC.2025-08-26RICHARD ALEXANDER MOORE JR. | pending |
| METHODS FOR ADMINISTRATION OF CERTAIN MUSCARINIC RECEPTOR AGONISTSFiled as NEUROCRINE BIOSCIENCES, INC.2025-08-26JASKARAN B. SINGH | pending |
| METHODS OF TREATMENTFiled as NEUROCRINE BIOSCIENCES, INC.2025-08-26JASKARAN B. SINGH | pending |
| METHODS OF TREATMENTFiled as NEUROCRINE BIOSCIENCES, INC.2025-08-26JASKARAN B. SINGH | pending |
| METHODS OF TREATMENTFiled as NEUROCRINE BIOSCIENCES, INC.2025-08-26JASKARAN B. SINGH | pending |
| METHODS FOR ADMINISTRATION OF CERTAIN MUSCARINIC RECEPTOR AGONISTSFiled as NEUROCRINE BIOSCIENCES, INC.2025-08-26ABIGAIL IRENE NASH | pending |
| METHODS OF TREATMENTFiled as Neurocrine Biosciences, Inc.2025-07-25Jaskaran B. Singh | pending |
| METHODS OF TREATMENTFiled as Neurocrine Biosciences, Inc.2025-07-25Jaskaran B. Singh | pending |
| CHEMICALLY MODIFIED PEPTIDES AND USE THEREOFFiled as NEUROCRINE BIOSCIENCES, INC.2025-06-18ADAM R. MEZO | pending |
| CHEMICALLY MODIFIED PEPTIDES AND USE THEREOFFiled as NEUROCRINE BIOSCIENCES, INC.2025-06-18ADAM R. MEZO | pending |
| CHEMICALLY MODIFIED PEPTIDES AND USE THEREOFFiled as NEUROCRINE BIOSCIENCES, INC.2025-06-18ADAM R. MEZO | pending |
| INGREZZA SPRINKLEFiled as Neurocrine Biosciences, Inc.2025-05-22Georgie Abraham GEORGE | pending |
| COMBINATION TREATMENTFiled as NEUROCRINE BIOSCIENCES, INC.2025-05-14ROBERT H. FARBER | pending |
| NLRP3 INFLAMMASOME INHIBITOR AND USE THEREOFA61K 31/50, C07D 401/12, C07D 471/04, C07D 487/04, A61P 37/00, A61P 37/02, A61P 37/06, A61P 29/00, A61K 31/501, A61K 31/502, A61K 31/504, A61K 31/53, C07B 59/002, C07B2200/05, C07D 237/20, C07D 237/26, C07D 237/34, C07D 253/07, C07D 405/12, C07D 409/12, C07D 495/04Filed as Neurocrine Biosciences, Inc.2025-04-30Lin Li | pending |
| COMPOUNDS AND COMPOSITIONS AS GPR52 MODULATORSC07D 401/04, C07D 401/12, A61P 25/00, C07D 213/68, C07D 231/56, C07D 401/14, C07D 405/12, C07D 413/12, C07D 417/12, C07D 471/04, C07D 491/052Filed as Neurocrine Biosciences, Inc.2025-04-25Neil J. Ashweek | pending |
| METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORSA61K 31/4375, A61K 31/473, A61K 31/4745, A61P 25/14, A61P 1/16, A61P 25/18, A61P 25/00, A61K 9/0053, A61K 9/48, A61K 31/4525, A61K 31/4709, A61K 31/495, C07D 455/06Filed as Neurocrine Biosciences, Inc.2025-04-23Christopher F. O'Brien | pending |
| TREATMENT OF DEPRESSIVE DISORDERS AND COGNITIVE IMPAIRMENTFiled as NEUROCRINE BIOSCIENCES, INC.2025-04-21JASKARAN B. SINGH | pending |
| METHODS OF ADMINISTERING 9-[4-(CYCLOHEXYLOXY)PHENYL]-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE WITHOUT SIDE EFFECTSFiled as NEUROCRINE BIOSCIENCES, INC.2025-04-21JASKARAN B. SINGH | pending |
| SUBSTITUTED PYRIDO[2,1-a]ISOQUINOLINES AS VMAT2 INHIBITORSC07D 471/04, A61P 25/18, A61P 25/00, A61K 31/4745Filed as Neurocrine Biosciences, Inc.2025-04-18Nicole Harriott | pending |
| CORTICOTROPIN RELEASING FACTOR RECEPTOR 2 (CRFR2) AGONISTSFiled as NEUROCRINE BIOSCIENCES, INC.2025-04-17RONGJUN HE | pending |
| CHEMICALLY MODIFIED PEPTIDES AND USE THEREOFFiled as NEUROCRINE BIOSCIENCES, INC.2025-04-17Adam R. MEZO | pending |
| VMAT2 INHIBITORS AND METHODS OF USEFiled as NEUROCRINE BIOSCIENCES, INC.2025-03-19BYRON A. BOON | pending |
| HEXAHYDRO-2H-PYRIDO[2,1-A]ISOQUINOLINE VMAT2 INHIBITORS AND METHODS OF USEFiled as Neurocrine Biosciences, Inc.2025-03-18Byron A. Boon | pending |
| CRYSTALLINE FORMSFiled as Neurocrine Biosciences, Inc.2025-03-14Scott Stirn | pending |
| TREATMENT OF DEPRESSIVE DISORDERSFiled as Neurocrine Biosciences, Inc.2025-03-06Jaskaran B. Singh | pending |
| TREATMENT OF DEPRESSIVE DISORDERSFiled as Neurocrine Biosciences, Inc.2025-03-06Jaskaran B. Singh | pending |
| METHODS FOR THE ADMINISTRATION OF CERTAIN VMAT2 INHIBITORSFiled as NEUROCRINE BIOSCIENCES, INC.2025-03-05MARTIN T. TAYLOR | pending |
| COMBINATION TREATMENTFiled as Neurocrine Biosciences Inc.2025-02-25Robert H. Farber | pending |
| VMAT2 INHIBITORS AND METHODS OF USEFiled as Neurocrine Biosciences, Inc.2025-02-21Byron A. Boon | pending |
| INGREZZA SPRINKLEFiled as Neurocrine Biosciences, Inc.2025-01-09Georgie Abraham George | pending |
| GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETOC07D 495/04, C07C 233/88, C07C 235/42, C07C 255/57, C07D 213/56, C07D 213/58, C07D 213/61, C07D 213/64, C07D 213/70, C07D 213/81, C07D 213/84, C07D 213/89, C07D 215/14, C07D 215/54, C07D 239/36, C07D 401/04, C07D 401/12, C07D 413/12, C07D 417/12, C07D 495/02, A61P 13/08, A61P 5/08, A61P 5/02, A61P 15/14, A61P 17/00, A61P 13/02, A61P 1/00, A61P 5/24, A61P 11/00, A61P 15/00, A61P 15/08, A61P 1/04, A61P 35/00, A61K 31/435Filed as Neurocrine Biosciences, Inc.2025-01-07Graham BEATON | pending |
| SOLID FORMS COMPRISING AN AMPA POSITIVE ALLOSTERIC MODULATORFiled as Neurocrine Biosciences, Inc.2024-12-20Christina M. COSTA | pending |
| FATTY ACID CONJUGATED CYCLIC PEPTIDESFiled as NEUROCRINE BIOSCIENCES, INC.2024-12-12ADAM R. MEZO | pending |
| METHODS FOR THE ADMINISTRATION OF CRF ANTAGONISTFiled as Neurocrine Biosciences, Inc.2024-12-11Eiry W. Roberts | pending |
| METHODS FOR THE ADMINISTRATION OF CRF ANTAGONISTFiled as Neurocrine Biosciences, Inc.2024-12-11Eiry W. Roberts | pending |
| DEUTERATED COMPOUNDSC07B 59/002, C07D 417/12, A61P 25/08, A61K 31/635, C07B2200/05Filed as Neurocrine Biosciences, Inc.2024-11-27Evan Smith | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on NBIX
Company overviewEverything on NBIX in one place, with the price.SEC filingsWhat NBIX's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat NBIX's own officers and directors buy and sell.Planned salesSales NBIX insiders have filed notice of.Executive payWhat NBIX awarded its chief executive, and what it became.Who owns itEvery manager reporting a position in NBIX.Funds holding itWhich funds and ETFs hold NBIX, and how big a bet.LobbyingWhat NBIX spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on NBIX's account, and who they worked for.